Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
U.S. Government Faces Brief Shutdown as Congress Delays Funding Deal 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
U.S. Stock Futures Edge Lower as Tech Earnings and Fed Decision Shape Market Sentiment 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
